| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $1.1M | +458.3% |
| R&D Expense | $82.1M | +79.5% |
| SG&A Expense | $33.7M | +240.4% |
| Operating Income | -$114.7M | -106.8% |
| Net Income | -$88.0M | -81.1% |
| EPS (Basic) | -$1.41 | +91.0% |
| EPS (Diluted) | -$1.41 | +91.0% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $257.1M | +3009.9% |
| Short-term Investments | $484.9M | +170.3% |
| Accounts Receivable | $781K | +748.9% |
| Current Assets | $754.2M | +288.5% |
| Total Assets | $754.8M | +278.7% |
| Current Liabilities | $21.4M | +49.9% |
| Total Liabilities | $21.4M | +47.6% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$78.7M | -72.3% |
| Capital Expenditures | $234K | — |
| Investing Cash Flow | -$300.8M | -148.2% |
| Financing Cash Flow | $628.3M | +622.2% |
| Free Cash Flow | -$78.9M | — |
| Stockholders' Equity |
| $733.4M |
| +695.8% |